Vos T., Allen C., Arora M. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259.
Derry S, Wiffen P, Moore A.Topical Nonsteroidal Anti-inflammatory Drugs for Acute Musculoskeletal Pain. JAMA. 2016 Feb 23;315(8):813-4.
Barthel HR, Axford-Gatley RA.Topical nonsteroidal anti-inflammatory drugs for osteoarthritis. Postgrad Med. 2010; 122(6):98-106.
Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134-142.
Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64(6):e99-e104.
Von Korff M et al. United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data The Journal of Pain, Vol 17, No 10 (October), 2016: pp 1068-1080
Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord. 2004;5:28.
Nicholson, Differential diagnosis: nociceptive and neuropathic pain. Am J Manag Care, 2006. 12(9 Suppl): p. S256-62.
This IRB-Approved study was supported by Pain Relief Technologies (PRT), the manufacturers and distributors of the Kailo Pain Relieving Patch. Jeffrey Gudin MD was compensated by Clarity Science LLC for his role as Principal Investigator of this IRB-approved Study. Peter Hurwitz is President of Clarity Science LLC, the CRO administering this IRB-approved Study. Derek Dietze, MA, was compensated for services by Clarity Science LLC for data evaluation and statistical analysis
IRB approval was obtained by IntegReview IRB Austin. Texas USA